Youth vaping: what the evidence shows about use, harms and quitting

E-cigarettes are the tobacco product American teenagers use most, and after years of alarm, youth vaping has fallen well below its peak [s1]. The best-documented harm is not an acute lung injury but a trajectory: adolescents who vape are several times more likely to go on to smoke conventional cigarettes than those who do not [s2]. Both facts are established, and holding them together is the honest summary of where the evidence stands.

How many young people vape, and the recent fall

The National Youth Tobacco Survey is the standard US measure. In 2024, current (previous-30-day) use of any tobacco product was reported by 10.1% of high school students, representing about 1.58 million, and 5.4% of middle school students, about 640,000 [s1]. Among all students, e-cigarettes were the most commonly used product at 5.9%, ahead of nicotine pouches at 1.8%, cigarettes at 1.4% and cigars at 1.2% [s1].

The direction of travel is downward. Between 2023 and 2024, the number of students using any tobacco product fell from 2.80 to 2.25 million, and e-cigarette use fell from 2.13 to 1.63 million [s1]. Among high school students specifically, current e-cigarette use dropped from 10.0% to 7.8% in a single year [s1]. Among middle school students, no statistically significant change occurred [s1]. This is a real decline from the peak years, though vaping remains the dominant form of youth tobacco use.

The clearest harm: vaping and later smoking

The health evidence on youth vaping is complicated by the fact that these products are relatively new, so long-term outcome data are thin. The most consistent signal is the "gateway" association. A systematic review and meta-analysis of adolescents aged 13 to 19 in Europe and North America found that teenagers who had ever used e-cigarettes had about 4.06 times the odds of later starting to smoke conventional cigarettes (95% confidence interval 3.00 to 5.48), pooling nine studies with follow-up between four and 24 months [s2]. Restricting the analysis to the four highest-quality studies lowered the estimate only slightly, to 3.71 times the odds (95% CI 2.83 to 4.86) [s2].

Association is not proof of cause, and the review's authors are careful about that: teenagers inclined to try one nicotine product may be inclined to try another. But the consistency of the finding across studies, and its persistence in the higher-quality subset, is why the review calls this an important health-related harm rather than a statistical artefact [s2]. Nicotine itself is the other established concern — it is addictive and the adolescent brain is still developing — which is the mechanism underlying both dependence and the smoking transition.

What is known about prevention

On what actually stops young people using tobacco, the US Preventive Services Task Force reviewed the primary-care evidence and drew a sharp line between prevention and cessation. It gives a B recommendation — meaning clinicians should provide it — that primary care clinicians offer interventions, such as education or brief counselling, to prevent tobacco use among school-aged children and adolescents [s3]. For helping young people who already use tobacco to quit, the USPSTF concluded the evidence was insufficient to assess the balance of benefits and harms, an I statement [s3]. In plain terms: keeping teenagers from starting has an evidence base; the clinical toolkit for getting them to stop does not yet.

That asymmetry is why population measures dominate the policy response. Our coverage of Australia's move to make vapes pharmacy-only and of survey data from Saudi Arabia shows regulators leaning on availability and price rather than clinical counselling, because that is where the stronger evidence sits.

How to read this without overreaching

The evidence supports a clear but bounded picture. Vaping is the most common form of youth tobacco use, its prevalence has fallen from the peak, and its best-established harm is a raised likelihood of moving on to cigarettes, alongside nicotine addiction [s1] [s2]. What the evidence does not yet provide is a long-run account of the direct health effects of vaping through a person's life, because the products have not existed long enough for those studies to mature.

Two limits matter. The gateway studies are observational, so residual confounding cannot be ruled out [s2]. And prevalence surveys rely on self-report and can miss the newest products; the rise of nicotine pouches in the 2024 data is a reminder that the youth nicotine market keeps shifting [s1]. Our related coverage of social media and adolescent wellbeing addresses another of the environmental pressures on this age group.

This article is informational and is not medical advice. It does not recommend any product or cessation method for an individual, and it is not a how-to; concerns about a young person's nicotine use should be discussed with a qualified clinician.